Skip to main content

New 'Autism Toolkit' for Clinicians Launched


NEW ORLEANS — A new "autism toolkit" designed to help clinicians diagnose and manage autism spectrum disorders (ASD) and provide resources for the families of these children has been launched by the American Academy of Pediatrics (AAP).
Released here at the AAP 2012 National Conference and Exhibition, the second edition of the autism toolkit is entitled Autism: Caring for Children With Autism Spectrum Disorders: A Resource Toolkit for Clinicians and includes the latest AAP guidelines on autism screening, surveillance, diagnosis, treatment, and referral.
According to the toolkit coeditor Susan E. Levy, MD, University of Pennsylvania School of Medicine, Philadelphia, it provides doctors with tools to help them "be more comfortable in their understanding of the policies put forward by the AAP for evaluating and managing ASD."
"We modelled it after the toolkit for attention-deficit/hyperactivity disorder, which has had very good uptake by pediatricians. We were inspired by how effective that was, and we think the new toolkit is equally great," said Dr. Levy, who is board certified in pediatrics and neurodevelopmental disabilities
According to Susan L. Hyman, chair of the autism subcommittee of the AAP Council on Children With Disabilities, this second edition, the first since 2007, was revised on the basis of feedback from primary care providers for ease of use and includes additional and updated topic areas related to medical, behavioral, and educational care.
Dr. Levy emphasized that the toolkit was developed with abundant input.
"We were part of the group that wrote the first version, and we were tasked with the revision. It went out for review to members of the Council, and even more importantly, to families with different-aged children with ASD. The information was vetted through families," she said.
The toolkit includes more than 70 tools for healthcare providers, including developmental screening questionnaires and screening tools, diagnostic criteria, treatment algorithms, family handouts in English and Spanish, record-keeping tools, and clinician fact sheets on specific health concerns.
Its main components include the following:
  • Practice-focused guidelines and recommendations: New and recently reaffirmed AAP clinical reports and policy statements on ASD identification, evaluation, and management.
  • Developmental screening and surveillance tools: Algorithms, questionnaires, growth charts, diagnostic criteria, Centers for Disease Control and Prevention developmental milestones, and record-keeping tools.
  • Visit preparation and tracking aids: Detailed guidance for facilitating ASD office visits; tools to track key steps in identification, diagnosis, intervention, and management.
  • Clinician fact sheets: Expert insights and advice on Asperger syndrome, sleep disorders, toilet training, nutrition, gastrointestinal disorders, seizures and epilepsy, psychopharmacology, complementary and alternative therapies, transition to adult care, and more.
  • Referral tools and time-savers: Ready-to-use early-intervention referral and follow-up forms.
  • Coding and billing guidance: Techniques to help ensure prompt, proper payment for ASD-related services.
  • Family education handouts in English and Spanish: Handouts for quick duplication and distribution; topics include behavioral challenges, early-intervention services, school-based services, medications, vaccines, toilet training, sleep problems, sibling issues, eating problems, transition to adulthood, and more.
Dr. Levy added that one of the most valuable additions is guidance for the medical workup of children with autism.
"We worked with a geneticist, for example. The information is up-to-date," she said.
David Matthews, MD, of Jonesboro, Arkansas, who is president of the state AAP chapter, attended a presentation by Dr. Levy and commented on the toolkit's value.
"I think it will be a very good resource for dealing with patients. In my practice, only 2 of us are trained for upper-level autism screening, and this toolkit will be especially helpful to physicians with less frequent contact with these patients," he said.
Early Recognition Critical
Commenting on the findings for Medscape Medical News, Laura Politte, MD, a child and adolescent psychiatrist and clinical instructor at Harvard Medical School in Boston, Massachusetts, noted that the prevalence of ASD is growing, and so it is more critical than ever that clinicians become more familiar with how to recognize the early signs of the disorder and make appropriate specialist referrals.
"Early recognition by pediatricians is particularly imperative, as outcomes for children with ASD can improve substantially with intensive educational and behavioral therapies instituted early in the course of development," said Dr. Politte, who is also an assistant in psychiatry and pediatrics at Massachusetts General Hospital.
She noted that the toolkit "has the potential to improve early detection of ASD and the quality of care throughout childhood for those affected."
Dr. Levy, Dr. Hyman, Dr. Matthews, and Dr. Politte have disclosed no relevant financial relationships.
American Academy of Pediatrics (AAP) 2012 National Conference and Exhibition. Presented October 20, 2012.

Comments

Post a Comment

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more